Type III secretion systems are toxin delivery systems that are present in a large number of pathogens. A hallmark of all type III secretion systems studied to date is that expression of one or more of their components is induced upon cell contact. It has been proposed that this induction is controlled by a negative regulator that is itself secreted by means of the type III secretion machinery. Although candidate proteins for this negative regulator have been proposed in a number of systems, for the most part, a direct demonstration of their role in regulation is lacking. Here, we report the discovery of ExsE, a negative regulator of type III secretion gene expression in Pseudomonas aeruginosa. Deletion of exsE deregulates expression of the type III secretion genes. We provide evidence that ExsE is itself secreted by means of the type III secretion machinery and physically interacts with ExsC, a positive regulator of the type III secretion regulon. Taken together, these data demonstrate that ExsE is the secreted negative regulator that couples triggering of the type III secretion machinery to induction of the type III secretion genes.
Type III secretion systems are toxin delivery systems that are present in a large number of pathogens. A hallmark of all type III secretion systems studied to date is that expression of one or more of their components is induced upon cell contact. It has been proposed that this induction is controlled by a negative regulator that is itself secreted by means of the type III secretion machinery. Although candidate proteins for this negative regulator have been proposed in a number of systems, for the most part, a direct demonstration of their role in regulation is lacking. Here, we report the discovery of ExsE, a negative regulator of type III secretion gene expression in Pseudomonas aeruginosa. Deletion of exsE deregulates expression of the type III secretion genes. We provide evidence that ExsE is itself secreted by means of the type III secretion machinery and physically interacts with ExsC, a positive regulator of the type III secretion regulon. Taken together, these data demonstrate that ExsE is the secreted negative regulator that couples triggering of the type III secretion machinery to induction of the type III secretion genes.
contact-dependent secretion ͉ pathogenesis ͉ virulence P seudomonas aeruginosa is an opportunistic pathogen that is responsible for a wide range of infections. It is a common hospital-acquired pathogen and is responsible for ventilatorassociated pneumonia in patients with underlying immune defects (1-3), as well as wound and catheter-associated infections. In healthy individuals, it is also a leading cause of contact lens keratitis (4), otitis externa (swimmer's ear), and hot-tub folliculitis (5, 6) . Additionally, P. aeruginosa is the most common pathogen in lung infections affecting cystic fibrosis patients and is the leading cause of morbidity and mortality in this patient group (7, 8) . The ability of Pseudomonas to cause infection is further exacerbated by a high level of resistance to antibiotics, which makes Pseudomonas infections difficult to treat (9) .
Pseudomonas has a wide arsenal of virulence factors at its disposal. Among these virulence factors are a variety of secreted factors, such as proteases (10) , phospholipases (11, 12) , and the AB toxin exotoxin A (13) . P. aeruginosa strains also posses a type III secretion system that allows them to deliver toxins (effectors) directly into the cytoplasm of a host cell (14) .
Four type III secreted toxins have been described in P. aeruginosa. Exoenzyme (Exo) S and ExoT are highly related proteins with two functional domains (15) . They both possess a rho-GAP domain, which causes cell rounding by effecting depolymerization of actin in targeted host cells (16, 17) . They also both contain an ADP-ribosylation domain, the cellular targets of which differ between ExoS and ExoT. ExoS ADP-ribosylates small ras-like proteins (18) (19) (20) , whereas ExoT targets CrkI and CrkII (21) . The other two exoenzymes described to date are ExoU (22, 23) , a potent phospholipase (24) , and ExoY, an adenylate cyclase (25) . Interestingly, the presence of ExoU and ExoS in the genome varies from strain to strain and appears to be mutually exclusive (26) . In this study, we have used strain PAK, whose genome contains the genes encoding ExoS, ExoT, and ExoY but not ExoU.
Expression of the type III secretion machinery and its effectors is regulated coordinately by action of the AraC-type transcription activator ExsA (27) . Expression is induced by cell contact and can also be induced in vitro by removal of calcium from the medium (28, 29) . Because induction depends on the presence of a functional type III secretion machinery (14, 30) , it has been proposed that induction is achieved by secretion of a negative regulator by means of the type III secretion system itself (31) . In recent years, a cascade of proteins has been discovered that influences the activity of ExsA. The first regulator in this cascade is ExsD, a cytoplasmic protein that binds ExsA and prevents it from activating gene expression (32) . Consequently, an exsD mutant expresses the type III secretion regulon constitutively, even in the presence of calcium. Secretion of proteins, however, is still low-calcium-dependent in an exsD mutant (32) . The next protein in the cascade is ExsC, an anti-anti-activator that can bind to ExsD and relieve repression of the regulon (31) . Overexpression of ExsC results in constitutive expression of the regulon. Conversely, deletion of exsC renders the cell incapable of inducing the type III secretion genes, even under low-calcium conditions (31) .
Type III secreted proteins are generally paired with a chaperone that is required to maintain these proteins in an exportcompetent state. ExsC resembles these chaperones, which led to the suggestion that, in an uninduced P. aeruginosa cell, ExsC is bound to and inactivated by an unknown type III secreted protein. When the type III secretion machinery is triggered, this unknown factor would be secreted, thereby releasing ExsC and allowing it to bind ExsD, thus activating ExsA (31) . Here, we report the discovery of the predicted ExsC inhibitor, ExsE, a small, type III secreted protein that binds tightly to ExsC and acts as a repressor of the type III secretion regulon.
Materials and Methods
Strains and Media Conditions. P. aeruginosa strains used in this study were derivatives of strain PAK and are listed in Table 1 , which is published as supporting information on the PNAS web site. Escherichia coli strain DH5␣ was used for cloning, and E. coli strain Sm10pir was used to mate plasmids into P. aeruginosa (both derived from laboratory stocks). Two-hybrid analysis was performed in E. coli strain KS1 (33, 34) , which harbors on its genome the lac promoter derivative p lacOR2-62 , driving expression of a linked lacZ reporter gene. Bacteria were grown in LuriaBertani medium supplemented with 10 mM MgCl 2 and in which the salt concentration was adjusted to 200 mM. Where indicated, calcium was removed from the media by addition of the chelator nitrilotriacetic acid (Sigma) to a final concentration of 10 mM.
Strain and Plasmid Construction. Details of strain and plasmid construction, as well as a table of plasmids and P. aeruginosa strains used in this study, are listed in Supporting Text, which is published as supporting information on the PNAS web site, and Table 1 .
Enzyme Assays. To assay exoS induction by removal of calcium from the media, bacteria were diluted 1:300 from overnight cultures and grown in Luria-Bertani medium for 2 h. At that point, cultures were split and diluted 1:1 into fresh, prewarmed media with or without nitrilotriacetic acid (final concentration of 10 mM) and incubated for another 3 h. ␤-Galactosidase activity was assayed by following the protocol described by Miller (35) . Cells were permeabilized by the addition of SDS and chloroform. All assays were performed in triplicate.
Cytotoxicity Assay. Intoxication of eukaryotic cells was monitored by the ability of the bacteria to cause cell rounding in cultured A549 lung epithelial cells. Cells were grown in RPMI supplemented with 10% FBS͞2 mM glutamine͞10 mM Hepes, pH 7.4. Cells were seeded into 24-well plates 1 day before the day of the experiment at Ϸ8 ϫ 10 4 cells per well. On the day of the experiment, the old medium was removed, the cells were washed two times with PBS, and fresh, prewarmed medium was added to the wells. The cells were infected with P. aeruginosa at a multiplicity of infection of 50 (assuming 10 5 cells per well) and incubated for 4 h at 37°C in an atmosphere of 5% CO 2 . The assay was stopped by removing the media and fixing the cells at room temperature with paraformaldehyde [a filtered solution of 4% paraformaldehyde in 150 mM KPO 4 (pH 7.4)]. Cell rounding was assayed by phase microscopy.
Western Blot Analysis. Overnight cultures of strains to be assayed were diluted 1:300 into fresh media, grown for 2 h, and then induced by diluting 1 ml of the culture into an equal volume of prewarmed media supplemented with nitrilotriacetic acid (NTA) (10 mM final concentration). As a control, a second milliliter of the culture was diluted into prewarmed media without NTA. The bacteria were then grown for another 30-60 min, after which the cells were chilled on ice. One milliliter of the culture was centrifuged, and protein from 0.5 ml of the culture supernatant was precipitated with trichloroacetic acid at a final concentration of 10%. The precipitate was pelleted by centrifugation, washed once with acetone, dried, and resuspended in SDS sample buffer. Cell pellets were resuspended directly in SDS sample buffer. All samples were normalized for OD 600 , boiled for 10 min to denature proteins, and separated by SDS͞PAGE. Western blot analysis was performed as described in ref. 36 .
Tandem Affinity Purification (TAP).
Cells were grown at 37°C with aeration in 200 ml of Luria-Bertani medium with carbenicillin at 150 g͞ml in 1-liter flasks to an OD 600 of Ϸ0.7 and then harvested by centrifugation at 4°C. Cells were resuspended in 10 ml of buffer 1 (20 mM KHepes, pH 7.9͞50 mM KCl͞0.5 mM DTT͞10% glycerol), harvested by centrifugation at 4°C, and resuspended in 1 ml of buffer 1 containing a mixture of protease inhibitors (Complete Mini, EDTA-free, Roche Molecular Biochemicals). Cell lysates were made by sonication of the cell suspension followed by centrifugation at 16,000 ϫ g at 4°C for 20 min. TAP was then performed essentially as described in ref. 37 except that cleavage with tobacco etch virus protease was performed overnight at 4°C. Proteins were subsequently concentrated by using Amicon Ultra-4 centrifugal filtration units with a 5-kDa molecular mass cutoff (Millipore).
Two-Hybrid Analysis. Two-hybrid analysis was performed as described in ref. 33 .
Results
ExsE Is a Negative Regulator of the Type III Secretion Regulon of P.
aeruginosa. The discovery of exsE was fortuitous. While researching an unrelated aspect of the regulation of the type III secreted effector ExoS, we noticed that a plasmid clone bearing the exsB region of the exsCBA operon (Fig. 1) prevented the induction of exoS expression. The plasmid included the small ORF PA1711. Because a similar clone bearing only exsB did not inhibit induction, the experiment implicated PA1711 as a negative regulator of exoS expression (data not shown). exoS is part of the type III secretion regulon. Its expression depends on ExsA and increases greatly upon induction of the regulon, making it an ideal reporter for the expression of the regulon (38) .
To determine whether PA1711 is indeed a negative regulator of exoS, we constructed a clean deletion of the ORF by allelic exchange and assayed the effect of the deletion on exoS expression. Deletion of PA1711 resulted in derepression of exoS expression ( Fig. 2A) , and overexpression of PA1711 was able to prevent induction of exoS in WT strain PAK (Fig. 2B) . Expression of PA1711 from a plasmid was also able to fully restore low-calcium-dependent expression in the PA1711 deletion mutant background. Taken together, these results indicate that PA1711 is a negative regulator of ExoS expression, and we therefore designated it exsE, in keeping with the previously established nomenclature.
If ExsE is indeed responsible for inactivating ExsC, then it should exert its negative regulatory effect by means of ExsC. A mutant lacking both exsC and exsE should be repressed (just like an exsC mutant) and not induce exoS expression upon removal of calcium from the medium. An exsC exsE double null mutant is, in fact, repressed. The defect could be rescued by expressing ExsC from a plasmid, which restored induction and calcium independence, as had been observed for the exsE null mutant (Fig. 2C ).
ExsE Is Not Required for Type III-Mediated Cytotoxicity or Low-
Calcium-Dependent Secretion. To assess whether an exsE mutant is still capable of intoxicating cells, we infected A549 cells with either WT PAK or mutant derivatives lacking exsE, pscC, or both exsE and pscC. An exsE mutant was fully capable of inducing cell rounding in A549 cells (Fig. 3A) . The intoxication depends on a functional type III secretion apparatus, because mutants lacking the outer membrane secretin gene, pscC, were unable to induce cell rounding. Moreover, the rate of intoxication was elevated in the exsE mutant, presumably due to the overexpression of the type III secretion machinery and the effector proteins (data not shown).
We next determined whether secretion in the exsE mutant is still low-calcium-dependent by assaying secretion of ExoS into the supernatant. Although expression of ExoS is clearly induced in the exsE mutant, secretion still depends on removal of calcium from the media, as well as a functional, type III secretion machinery (Fig. 3B) . Genetic organization of the type III secretion regulatory locus. Promoters are indicated by arrows. All genes in this chromosomal fragment are depicted as solid black arrows, except exsE, which is striped. Numbers below the fragment indicate size in base pairs.
ExsE Is Secreted Under Low-Calcium
Conditions. An important prediction of the model is that ExsE is secreted from the cell upon triggering of the type III secretion system, thereby freeing ExsC. We used the Myc5-tagged version of ExsE (ExsE-Myc5) to determine whether ExsE is secreted from the cell under lowcalcium conditions. ExsE-Myc5 is functional because induction of exoS in this strain closely mirrors that of the WT parent (Fig.   2 A) . Analysis of ExsE-Myc5 localization by Western blot demonstrated that the protein is, in fact, secreted from the cell upon removal of calcium from the medium (Fig. 4) . Furthermore, its export depends on the presence of an intact type III secretion system, because mutating the secretin gene, pscC, prevented export (Fig. 4) .
ExsE Binds ExsC. The proposed model for regulation predicts that ExsE directly binds ExsC. We therefore set out to determine whether ExsE and ExsC interact in vivo, by using two unrelated methods. First, we used a two-hybrid system to monitor the interaction in bacterial cells. The particular bacterial two-hybrid system we decided to use relies on the ability of interacting proteins to induce transcription of lacZ from a test promoter carrying a suitably positioned operator in its upstream region. One of the putative interacting proteins is fused to the DNA-binding protein cI; the other protein is fused to the ␣-subunit of RNA polymerase. If the two proteins interact, promoter occupancy by RNA polymerase is increased, resulting in elevated expression of the reporter gene, lacZ (33) . The results of the analysis are shown in Fig. 5A . ExsE and ExsC interact very strongly in this system, showing elevated expression from the test promoter even without induction of the fusion proteins. As expected, ExsC and ExsD also interact in this system. However, ExsE and ExsD do not interact, demonstrating the specificity of the detected interactions. None of the fusion proteins interacts with the ␣-subunit of RNA polymerase or with cI by itself. Furthermore, switching the fusion partners yielded the same result, suggesting that the data are not a result of a bias inherent in the particular fusion partners we chose.
We also used a biochemical approach to study the ExsE-ExsC interaction. TAP tagging is a recently developed technique that allows the isolation of protein complexes, using relatively mild purification conditions (37) . It relies on attaching a protein moiety that is composed of two affinity tags to the target protein.
The tagged protein is expressed in the cell and purified by two sequential affinity purification steps, resulting in a highly purified protein complex. We fused the TAP tag to the amino terminus of ExsC and expressed it in P. aeruginosa. The ExsC-TAP fusion protein is still able to induce exoS expression and is therefore active (data not shown). As a control, we fused the TAP tag to the amino terminus of an unrelated protein, the transcription elongation factor NusA. The tagged proteins were expressed separately in a P. aeruginosa strain in which the chromosomal copy of exsE had been modified with the Myc5-tag, as mentioned above. The presence of the Myc5-tagged ExsE was monitored by Western blot analysis. As shown in Fig. 5B , the Myc5-tagged protein was present in the whole-cell lysate of both strains. The TAP-tagged fusion proteins were also detected in the Western blot, presumably due to the protein A moiety of the TAP tag, which is later cleaved off during the purification procedure. ExsE-Myc5 only copurified with the TAP-tagged ExsC, not NusA-TAP, confirming the two-hybrid interaction data.
A pcrV Mutant Secretes ExoS Constitutively.
A controversy has arisen in the literature with respect to the ability of a pcrV mutant of P. aeruginosa to secrete type III effectors constitutively. This point is important in the context of ExsE function, because a pcrV mutant expresses type III effectors constitutively (32, 39) (A.R. and J.J.M., unpublished data). If the pcrV mutant were constitutive for exoS expression but not secretion, it would suggest that the model for ExsE function is wrong.
PcrV is involved in allowing PopD, a component of the translocase, to insert into the membrane of a target cell (40) . PcrV has garnered some attention in the past because it is surface displayed, and antisera directed against PcrV are protective in an animal model (41) (42) (43) (44) .
Initial studies performed in strain PA103 seemed to suggest that a mutant of pcrV secretes effector proteins into the media even under calcium-replete conditions (32) . Subsequent studies performed in strain CHA suggested that secretion was lowcalcium-dependent (40) , whereas data from strain PAK were variable but suggested little to no secretion in a pcrV mutant in calcium-replete media (39, 45) . We have constructed pcrV mutants in both PAK and PA103 and complemented them to ensure that the mutants are indeed only defective in the production of PcrV (data not shown). We were able to reproduce the phenotypes described in the literature. The PA103 pcrV mutant secreted ExoU constitutively, whereas the PAK mutant appeared to secrete ExoS only after the removal of calcium from the media. Because these experiments were performed in parallel and in identical batches of media, differences in culture conditions could be ruled out. However, we did detect a series of low-molecular-weight fragments that reacted with the ExoS antiserum in supernatants of the PAK-derived mutant, which suggested that perhaps the difference observed between PA103 and PAK was due to the fact that PAK produces a chelatorsensitive protease. We performed pulse-chase experiments to test this hypothesis and were able to confirm that the pcrV mutant of PAK did, in fact, secrete ExoS constitutively. Surprisingly, ExoS did not appear to be any less stable in samples to which no chelator had been added (data not shown), suggesting that degradation was either a function of media (Mops minimal media versus Luria-Bertani medium) or growth phase (the pulse-chase experiments were performed at an OD 600 of Ϸ0.3). Western blot analysis of supernatants derived from both WT and pcrV mutant PAK demonstrated that degradation of ExoS depends on cell density. ExoS is readily detectable in pcrV mutant culture supernatants in early logarithmic phase (OD 600 ϭ 0.3), even without addition of chelator (Fig. 6) . Conversely, supernatants harvested at late-log͞early stationary phase (OD 600 ϭ 1.4) did not contain any full-length ExoS (Fig.  6) . Instead, the supernatant harvested from the pcrV mutant clearly contained breakdown products that react with the ExoS antiserum that were not visible in the uninduced WT culture supernatant (Fig. 6 ).
Discussion
The type III secretion genes in P. aeruginosa are regulated by a cascade of regulators that ultimately determine activity of the master regulator, ExsA. In uninduced bacteria, ExsA is complexed with ExsD, which inhibits ExsA function. Whether ExsD binds ExsA is determined by ExsC, which can inhibit the activity of ExsD, thereby allowing ExsA to activate gene expression. In turn, ExsC is proposed to interact with a hypothetical secreted protein. Under noninducing conditions, ExsC would be bound to this protein and thus prevented from binding to ExsD and activating ExsA. Under inducing conditions, the protein would be secreted, allowing ExsC to inhibit ExsD and release ExsA (Fig. 7) .
Here, we describe ExsE, a small, highly charged protein that is secreted in a type III-dependent manner and serves as a negative regulator of type III secretion gene expression in P.
aeruginosa. ExsE is only 82 aa in length, 13 aa of which are positively charged and 11 negatively charged. It has no significant homology to any other protein in GenBank. An exsE null mutant is constitutive for exoS expression, whereas overexpression of ExsE in the cell prevents induction of the regulon. The constitutive expression in an exsE null mutant depends on the presence of functional ExsC, suggesting that ExsE, as predicted by the model, exerts its effect by inhibiting ExsC. Consistent with this observation, we have demonstrated in two independent assays that ExsE binds ExsC in vivo.
The exact details of how the regulation is achieved remain to be elucidated. The simplest model, which had been proposed previously (31) , holds that ExsE binding to ExsC disrupts the complex between ExsC and ExsD, thereby allowing free ExsD to bind ExsA. This model may not necessarily be correct, however, because one could also envision ExsE modifying the activity of a complex between ExsC and ExsD without causing the proteins to dissociate. Although a preliminary experiment that was aimed at disrupting the interaction of ExsC and ExsD in a two-hybrid system by overproduction of ExsE was unsuccessful, this result could be explained in any number of ways, including relative expression levels of the interaction partners. Further experiments will be needed to elucidate how the activation cascade functions in molecular detail.
Expression of type III secretion-related genes is regulated in all organisms in which they have been described. In most cases, an AraC-type regulator is at the base of the regulatory cascade. There are now a number of examples in which activity of this regulator depends on interaction with a second protein ligand. In the case of P. aeruginosa, two regulators that bind ExsA directly have been described, PtrA and ExsD (32, 46) . In Salmonella, the type III secretion chaperone SicA binds and activates InvF, a regulator that is responsible for the transcription of the Salmonella pathogenicity island I (Spi I) type III secretion genes in this organism (47) . This result implied a model whereby SicA is bound to its secretion substrates, SipB and SipC, when Salmonella are not secreting. When secretion is triggered, SipB and SipC are transported out of the cell, freeing SicA to bind InvF and induce transcription (48) . A similar model has been proposed in Shigella, where the type III secretion chaperone IpgC activates the AraC-type regulator MxiE (49) . In Yersinia, expression of type III secretion genes also depends on an intact type III secretion apparatus. The mechanism of regulation that is best understood, however, involves posttranscriptional regulation by the secretion chaperone LcrH. When LcrH is complexed with its cognate secretion substrate, YopD, it represses expression of type III secretion-associated mRNAs (50) . Secretion of YopD relieves this repression. Accordingly, a yopD deletion mutant results in constitutive expression in this system, even in the context of a mutation that inactivates the secretion apparatus (51) . Another secreted negative regulator, LcrQ͞YscM, has been described in Yersinia, and it is also involved in posttranslational regulation of effector expression and acts in concert with YopD (52) (53) (54) . The underlying principle in all these systems is the same: The negative regulator at the top of the regulatory cascade is a type III secreted protein. The details of the regulation, however, appear to differ among the systems. In Shigella and Salmonella, the protein binding the master regulator is a type III secretion chaperone that acts as a coactivator. In Yersinia, the chaperone-substrate complex binds mRNAs to prevent expression. In P. aeruginosa, it is an anti-activator, ExsD, whose activity is regulated by a type III secretion chaperone, ExsC.
This principle of secreting a regulator is also reminiscent of flagellar biosynthesis regulation. In this case, expression of the late flagellar biosynthesis genes is repressed by FlgM, an anti-sigma factor that binds to the flagellar biosynthesis-specific sigma factor, sigma 28. Once the basal body and hook of the flagellum have been synthesized, the anti-sigma factor is secreted from the cell by means of the flagellum, freeing sigma 28 (55) .
Pseudomonas infections are a significant problem in hospitals and are difficult to treat. The two-hybrid constructs, as well as some of the mutants described in this article, can be readily adapted for high-throughput screens of small molecules that mimic ExsE function and prevent induction of type III secretion gene expression in P. aeruginosa. Such small-molecule drugs would represent a novel class of antimicrobial agents aimed at inactivating one of the main virulence factors of P. aeruginosa.
Our data complete the previously proposed model for regulation of the type III genes in P. aeruginosa. The bacterium senses triggering of the type III secretion machinery by secreting a negative regulator, ExsE. With all of the basic components in hand, it will now be possible to determine how the regulatory cascade functions on a molecular level, with the hope that this understanding will be converted into new therapeutics aimed at treating P. aeruginosa infections.
